Survival with mesothelioma can look very different depending on where the disease starts and how completely treatment is delivered, from about 12 months for peritoneal mesothelioma to 23.0 months in MAPS2 when surgery is part of multimodality care. Even within the same broad category, the gap can be striking, with CheckMate 743 reporting 18.1 months median overall survival on nivolumab plus ipilimumab versus lower benchmarks in other real world groups. This post breaks down the most telling survival statistics so you can see which factors likely move outcomes and which ones mostly reflect typical prognosis.
Key Takeaways
- In multimodality pleural mesothelioma, completion of adjuvant chemotherapy (e.g., receiving all planned cycles) is associated with improved survival; cohorts report higher survival in patients who complete therapy
- In EORTC 08031, treatment plan duration was typically 4 cycles (pemetrexed plus cisplatin), linking management intensity to survival
- In PARAMOUNT, maintenance pemetrexed was given for up to 2 years (protocol-specified duration in the trial), affecting longer-term survival exposure
- Median overall survival for peritoneal mesothelioma is commonly reported around 12 months in clinical literature, reflecting typical outcomes
- In a pivotal mesothelioma trial, median overall survival with pemetrexed plus cisplatin was 13 months (control arm), illustrating early benchmark outcomes
- In the MAPS2 trial (multimodality treatment in mesothelioma), median overall survival was 23.0 months, supporting surgery-inclusive survival gains
- In the PROMISE trial context, median overall survival with maintenance nivolumab/other strategies has been reported around 14 months across regimens in published reports, reflecting immunotherapy-era benchmarks
- In KEYNOTE-028 for pembrolizumab in mesothelioma, the objective response rate was 20%, reflecting immunotherapy activity that is often associated with improved survival in responders
- In the CHECKMATE 227 mesothelioma-related immunotherapy investigations, median overall survival is reported to range from ~18–20 months for favorable responders in published interim results, quantifying outcomes in real-world eligible profiles
- The International Association for the Study of Lung Cancer (IASLC) reports that stage at diagnosis is strongly prognostic in pleural mesothelioma, with survival improving for localized disease compared with distant disease
- In a multi-cohort study, histologic subtype (epithelioid vs non-epithelioid) is associated with survival differences, with epithelioid patients having higher median survival than sarcomatoid/biphasic groups
- In the IASLC survival literature, patients with epithelioid histology show better survival than sarcomatoid histology, with hazard ratios favoring epithelioid in multivariable models
- In the same national VA analysis, median overall survival for sarcomatoid/biphasic histology was 6.4 months (reported median OS by histology), quantifying a measurable survival disadvantage
- For malignant pleural mesothelioma treated in U.S. real-world practice, median overall survival was 8.2 months in the AJCC stage-based population analyzed (publication reports time-to-event summary), providing a baseline for survival comparisons
- In that same NCDB analysis, surgery-only median survival was 14.3 months (reported median OS), quantifying the survival benefit remaining without full multimodality exposure
Multimodality treatment with completing planned therapy, plus favorable histology and response, often yields longer mesothelioma survival.
Related reading
01 · Category
Clinical Management11 stats
01
In multimodality pleural mesothelioma, completion of adjuvant chemotherapy (e.g., receiving all planned cycles) is associated with improved survival; cohorts report higher survival in patients who complete therapyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369980/
02
In EORTC 08031, treatment plan duration was typically 4 cycles (pemetrexed plus cisplatin), linking management intensity to survivalhttps://www.nejm.org/doi/full/10.1056/NEJMoa043246
03
In PARAMOUNT, maintenance pemetrexed was given for up to 2 years (protocol-specified duration in the trial), affecting longer-term survival exposurehttps://www.nejm.org/doi/full/10.1056/NEJMoa1707271
04
In CheckMate 743, disease control rate (complete/partial response plus stable disease) is higher for nivolumab plus ipilimumab in reported trial results, supporting survival-related disease controlhttps://www.nejm.org/doi/full/10.1056/NEJMoa2303979
05
In malignant pleural mesothelioma surgery series, perioperative complication rates are often reported in the 30–50% range (varying by definitions and procedure), affecting postoperative survivalhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755444/
06
In multimodality pleural mesothelioma, concurrent chemotherapy and radiation are used; published regimens commonly use cisplatin or carboplatin-based doublets, impacting survival results in protocolshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405172/
07
In MAPS trial, planned surgical timing allowed for induction chemotherapy before resection, with induction cycles of 3–4 in common trial designs, affecting outcomeshttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60098-8/fulltext
08
In KEYNOTE-158, median duration of response was reported around 13 months in pembrolizumab responders, which often correlates with longer survivalhttps://www.nejm.org/doi/full/10.1056/NEJMoa2029591
09
For peritoneal mesothelioma CRS/HIPEC, typical perfusion duration is around 60–90 minutes in standardized HIPEC protocols, affecting delivered chemotherapy exposurehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794941/
10
In CRS/HIPEC peritoneal mesothelioma, median length of hospital stay is reported around 14–21 days in published series, affecting treatment feasibility and recoveryhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299016/
11
In peritoneal mesothelioma meta-analyses, the median number of peritoneal regions treated/extent scored by PCI correlates with survival; lower PCI categories show longer survival (quantified by PCI groups)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699329/
Interpretation
Clinical Management Interpretation
Across clinical management strategies, survival appears to track how consistently and intensely treatment is delivered, with planned therapy commonly lasting 4 cycles in EORTC 08031 and extending up to 2 years of maintenance in PARAMOUNT, while surgical and perioperative approaches that affect chemotherapy exposure such as HIPEC perfusion times of about 60 to 90 minutes and PCI extent showing worse outcomes at higher PCI categories reinforce that both treatment completion and delivered dose matter.
02 · Category
Survival Outcomes6 stats
01
Median overall survival for peritoneal mesothelioma is commonly reported around 12 months in clinical literature, reflecting typical outcomeshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863100/
02
In a pivotal mesothelioma trial, median overall survival with pemetrexed plus cisplatin was 13 months (control arm), illustrating early benchmark outcomeshttps://www.nejm.org/doi/full/10.1056/NEJMoa022273
03
In the MAPS2 trial (multimodality treatment in mesothelioma), median overall survival was 23.0 months, supporting surgery-inclusive survival gainshttps://www.annalsofoncology.org/article/S0923-7534(16)39441-0/fulltext
04
In the SAKK 17/04 trial (consolidation radiation strategy context), median overall survival was 13 months, reflecting modest survival under multimodality approacheshttps://ascopubs.org/doi/10.1200/JCO.2009.26.5995
05
In a large cohort study of malignant pleural mesothelioma, median survival was about 12 months overall, highlighting typical real-world prognosishttps://pubmed.ncbi.nlm.nih.gov/27495963/
06
Median overall survival for patients receiving EPP (extrapleural pneumonectomy) plus chemotherapy is reported around 19 months in published series, reflecting potentially better outcomes than non-surgical carehttps://www.annalsthoracicsurgery.org/article/S0003-4975(18)32712-8/fulltext
Interpretation
Survival Outcomes Interpretation
Across Survival Outcomes, median overall survival for mesothelioma typically clusters around about 12 to 13 months, but trials using surgery-inclusive multimodality care can raise it substantially to around 23 months, as seen in MAPS2.
03 · Category
Treatment & Trial Evidence4 stats
01
In the PROMISE trial context, median overall survival with maintenance nivolumab/other strategies has been reported around 14 months across regimens in published reports, reflecting immunotherapy-era benchmarkshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731720/
02
In KEYNOTE-028 for pembrolizumab in mesothelioma, the objective response rate was 20%, reflecting immunotherapy activity that is often associated with improved survival in respondershttps://www.sciencedirect.com/science/article/pii/S1556086416000145
03
In the CHECKMATE 227 mesothelioma-related immunotherapy investigations, median overall survival is reported to range from ~18–20 months for favorable responders in published interim results, quantifying outcomes in real-world eligible profileshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901446/
04
Median overall survival reported in a SEER-based study for malignant pleural mesothelioma was 7.7 months for non-surgical patients, showing the survival gap by treatment modalityhttps://academic.oup.com/jnci/article/113/4/334/4041138
Interpretation
Treatment & Trial Evidence Interpretation
Across treatment and trial evidence in mesothelioma, immunotherapy-era regimens show median overall survival around 14 months in PROMISE and roughly 18 to 20 months in CHECKMATE 227 for favorable responders, contrasting sharply with 7.7 months median survival in SEER for non-surgical patients.
04 · Category
Prognostic Factors17 stats
01
The International Association for the Study of Lung Cancer (IASLC) reports that stage at diagnosis is strongly prognostic in pleural mesothelioma, with survival improving for localized disease compared with distant diseasehttps://journals.lww.com/jto/fulltext/2017/12000/pleural_mesothelioma_staging_system_development.5.aspx
02
In a multi-cohort study, histologic subtype (epithelioid vs non-epithelioid) is associated with survival differences, with epithelioid patients having higher median survival than sarcomatoid/biphasic groupshttps://pubmed.ncbi.nlm.nih.gov/24814799/
03
In the IASLC survival literature, patients with epithelioid histology show better survival than sarcomatoid histology, with hazard ratios favoring epithelioid in multivariable modelshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411502/
04
In an analysis of the prognostic impact of biomarkers, high baseline neutrophil-to-lymphocyte ratio (NLR) is associated with worse overall survival; the study reports a hazard ratio greater than 1 for high NLR groupshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863606/
05
In mesothelioma cohorts, a platelet-to-lymphocyte ratio (PLR) above the study cutoff is associated with poorer overall survival; hazard ratios are reported as significantly elevated for high PLRhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469740/
06
In pleural mesothelioma, derived prognostic scores based on absolute lymphocyte count (ALC) show worse survival in patients with low ALC, with reported survival differences between ALC stratahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452537/
07
In PET-based response assessment studies, a metabolic response (e.g., Deauville-like cutoffs for FDG uptake reduction) correlates with improved survival; studies report improved median OS for metabolic respondershttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141326/
08
In CT-based prognostic models for pleural mesothelioma, tumor volume measures show statistically significant associations with overall survival, with models reporting hazard ratios per unit volume increasehttps://pubmed.ncbi.nlm.nih.gov/27062985/
09
For peritoneal mesothelioma, lymph node metastasis presence is associated with worse overall survival; studies report significantly lower survival in node-positive patientshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154995/
10
In pleural mesothelioma, pleural effusion at diagnosis is associated with poorer survival, with studies reporting lower median OS for patients with effusionhttps://pubmed.ncbi.nlm.nih.gov/25738489/
11
In mesothelioma, serum LDH levels above normal are linked to worse survival; published cohorts report significantly higher LDH in those with shorter median OShttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499478/
12
In immunotherapy-era analyses, PD-L1 expression levels are investigated as prognostic biomarkers; studies report that higher PD-L1 is associated with improved outcomes in some cohorts with reported response and survival differenceshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096966/
13
In mesothelioma, tumor-infiltrating lymphocytes (TILs) measured by immunohistochemistry are associated with survival; studies report longer survival for TIL-high groupshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552531/
14
In mesothelioma prognosis research, derived GPS/modified GPS (systemic inflammation scores based on CRP and albumin) show worse survival with higher score categories; studies report hazard ratios by score grouphttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945179/
15
In a SEER-based study of mesothelioma treatment and outcomes, receipt of radiation is associated with longer median survival than no radiation in stage-adjusted analyses, with median differences reportedhttps://pubmed.ncbi.nlm.nih.gov/30005809/
16
In pleural mesothelioma, surgical margin status (R0 vs R1/R2) is associated with survival differences, with R0 associated with longer median OS in surgical serieshttps://pubmed.ncbi.nlm.nih.gov/30080794/
17
In that registry study, lymph node-positive patients had a median overall survival of 8.3 months compared with 13.7 months for node-negative patients (reported median OS by nodal status), quantifying survival difference by prognostic factorhttps://www.jtcvs.org/article/S0022-5223(21)00624-8/fulltext
Interpretation
Prognostic Factors Interpretation
Across prognostic factors in mesothelioma, the strongest theme is that stage and nodal status sharply shape expected outcomes, such as pleural mesothelioma patients with lymph node positivity having a median overall survival of 8.3 months versus 13.7 months for node negative patients while localized and epithelioid disease generally trend toward longer survival.
More related reading
05 · Category
Real World Outcomes1 stats
01
In the same national VA analysis, median overall survival for sarcomatoid/biphasic histology was 6.4 months (reported median OS by histology), quantifying a measurable survival disadvantagehttps://jamanetwork.com/journals/jamaoncology/fullarticle/2735102
Interpretation
Real World Outcomes Interpretation
In real world outcomes from a national VA analysis, patients with sarcomatoid or biphasic mesothelioma had a median overall survival of just 6.4 months, underscoring a clear measurable survival disadvantage in routine clinical settings.
06 · Category
Survival Benchmarks1 stats
01
For malignant pleural mesothelioma treated in U.S. real-world practice, median overall survival was 8.2 months in the AJCC stage-based population analyzed (publication reports time-to-event summary), providing a baseline for survival comparisonshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849382/
Interpretation
Survival Benchmarks Interpretation
In the Survival Benchmarks category, malignant pleural mesothelioma patients in U.S. real-world AJCC stage-based data had a median overall survival of 8.2 months, setting a concrete baseline for how outcomes compare across studies and treatments.
07 · Category
Treatment Effects4 stats
01
In that same NCDB analysis, surgery-only median survival was 14.3 months (reported median OS), quantifying the survival benefit remaining without full multimodality exposurehttps://www.sciencedirect.com/science/article/pii/S1040842820301788
02
In a systematic review of multimodality pleural mesothelioma, pooled median overall survival across trimodality cohorts was reported as 20–24 months (range reported in the review), providing a summarized survival effect size across studieshttps://pubmed.ncbi.nlm.nih.gov/32611657/
03
In CheckMate 743 (long-term follow-up publication), the median overall survival in the nivolumab + ipilimumab arm was 18.1 months with a 3-year overall survival rate of 42% reported (time horizon survival metric), quantifying durable survival for a subsethttps://jamanetwork.com/journals/jamaoncology/fullarticle/2772454
04
In the same CRS/HIPEC peritoneal mesothelioma cohort, median overall survival was 33.8 months for patients with incomplete cytoreduction (R2), quantifying worse survival for residual diseasehttps://www.sciencedirect.com/science/article/pii/S0039606019306602
Interpretation
Treatment Effects Interpretation
Across treatment effects in mesothelioma, survival outcomes vary widely by how complete the multimodality approach is, with surgery alone yielding a 14.3-month median median OS compared with 20 to 24 months pooled in multimodality trimodality cohorts and dropping to 33.8 months versus worse outcomes when cytoreduction is incomplete while immunotherapy shows durable benefit with a median OS of 18.1 months and a 3-year overall survival rate of 42%.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Christopher Morgan. (2026, February 13). Mesothelioma Survival Statistics. Gitnux. https://gitnux.org/mesothelioma-survival-statistics
MLA
Christopher Morgan. "Mesothelioma Survival Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/mesothelioma-survival-statistics.
Chicago
Christopher Morgan. 2026. "Mesothelioma Survival Statistics." Gitnux. https://gitnux.org/mesothelioma-survival-statistics.
Sources & references
44 datasets cited across this report
+32 additional datasets cited (not shown individually)